Clear Search

Showing 1 result for “Gladman D” published 2024.

March 2024

TYK2: An emerging therapeutic target in rheumatic disease

Nat Rev Rheumatol 2024;20(4):232–40 DOI 10.1038/s41584-024-01093-w

TYK2 inhibitors hold promise for the treatment of a distinct spectrum of autoimmune diseases, including SLE, and could potentially have a safety profile that differs from other JAK inhibitors.

more…